RAYONIER ADVANCED MATERIALS INC.
For the period ended May 13, 2026. Filed Mar 30, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 13, 2026 · Filed Mar 30, 2026
Contents
Pay Versus Performance
In accordance with rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding executive compensation for our principal executive officer (PEO) and Non-PEO NEOs and Company performance for the fiscal years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown.
| Year · Summary Compensation Table Total for First PEO(1)($) · Summary Compensation Table Total for Second PEO(1)($) · Summary Compensation Table Total for Third PEO(1)($) · Compensation Actually Paid to First PEO(1),(2),(3)($) · Compensation Actually Paid to Second PEO(1),(2),(3)($) · Compensation Actually Paid to Third PEO(1),(2),(3)($) · Average Summary Compensation Table Total for Non-PEO NEOs(1)($) · Average Compensation Actually Paid to Non-PEO NEOs(1),(2),(3)($) · Value of Initial Fixed $100 Investment based on:(4) · Net Income($ Millions) · Adjusted EBITDA($ Millions)(5) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TSR ($) · Peer Group TSR ($) | ||||||||||||
| 2025 | - | - | 5,138,573 | - | - | 918,075 | 1,288,989 | 632,264 | 90.34 | 138.87 | (420) | 133 |
| 2024 | - | - | 3,669,650 | - | - | 8,177,479 | 1,182,241 | 2,129,782 | 126.53 | 125.63 | (39) | 222 |
| 2023 | - | - | 3,732,138 | - | - | (1,199,645) | 1,127,116 | (247,468) | 62.12 | 125.68 | (102) | 139 |
| 2022 | - | 7,992,927 | 3,164,731 | - | 5,047,378 | 6,344,838 | 1,641,145 | 2,800,039 | 147.24 | 111.67 | (15) | 177 |
| 2021 | 5,665,507 | - | - | 3,806,923 | - | - | 1,336,480 | 926,166 | 87.58 | 127.28 | 66 | 127 |
| (1) | Paul Boynton served as First PEO until December 31, 2021. Vito Consiglio served as Second PEO until May 31, 2022. De Lyle W. Bloomquist served as Third PEO from May 31, 2022 to January 5, 2026. The individuals comprising the Non-PEO NEOs for each year presented are listed below. |
| 2021 - 2022 | 2023 - 2025 |
| Marcus J. Moeltner | Marcus J. Moeltner |
|---|---|
| Joshua C. Hicks | Joshua C. Hicks |
| William Manzer | Michael D. Osborne |
| James Posze | R. Colby Slaughter |
| (2) | The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below. |
| (3) | Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the respective PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards column are the totals from the Stock Awards column set forth in the Summary Compensation Table. |
| Year | Summary Compensation Table Total for Third PEO ($) | Exclusion of Stock Awards for Third PEO ($) | Inclusion ofEquity Values for Third PEO ($) | Compensation Actually Paid to Third PEO ($) |
|---|---|---|---|---|
| 2025 | 5,138,573 | (2,649,975) | (1,570,523) | 918,075 |
| Year | Average Summary Compensation Table Total for Non-PEO NEOs ($) | Average Exclusion of Stock Awards for Non-PEO NEOs ($) | Average Inclusion of Equity Values for Non-PEO NEOs ($) | Average Compensation Actually Paid to Non-PEO NEOs ($) |
|---|---|---|---|---|
| 2025 | 1,288,989 | (475,532) | (181,193) | 632,264 |
EXECUTIVE COMPENSATION TABLES AND RELATED INFORMATION
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
| Year | Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Third PEO ($) | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Third PEO ($) | Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Third PEO ($) | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Third PEO ($) | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Third PEO ($) | Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Third PEO ($) | Total - Inclusion ofEquity Values for Third PEO ($) |
|---|---|---|---|---|---|---|---|
| 2025 | 844,166 | (2,065,331) | - | (349,358) | - | - | (1,570,523) |
| Year | Average Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs ($) | Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs ($) | Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs ($) | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non-PEO NEOs ($) | Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs ($) | Average Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Non-PEO NEOs ($) | Total - Average Inclusion ofEquity Values for Non-PEO NEOs ($) |
|---|---|---|---|---|---|---|---|
| 2025 | 236,855 | (350,827) | - | (67,221) | - | - | (181,193) |
| (4) | The Peer Group TSR set forth in this table utilizes the S&P 500 Materials Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2025. The comparison assumes $100 was invested for the period starting December 31, 2020, through the end of the listed year in the Company and in the S&P 500 Materials Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. |
| (5) | We determined Adjusted EBITDA to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2025. |
| 2026 RYAM PROXY STATEMENT | 59 |
EXECUTIVE COMPENSATION TABLES AND RELATED INFORMATION
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and TSR
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and the cumulative TSR over the five most recently completed fiscal years for the Company and the S&P 500 Materials Index.
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and our net income during the five most recently completed fiscal years.
EXECUTIVE COMPENSATION TABLES AND RELATED INFORMATION
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Adjusted EBITDA
The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Adjusted EBITDA during the five most recently completed fiscal years.
Tabular List of Most Important Financial Performance Measures
The following table presents the financial performance measures that the Company considers to have been the most important in linking Compensation Actually Paid to our PEO and the Non-PEO NEOs for 2025 to Company performance. The measures in this table are not ranked.
Three-year cumulative Adjusted EBITDA
Relative TSR
Adjusted Operating Cash Flow
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.